Non-GAAP Adjustments This quarter, our GAAP net earnings and GAAP EPS included a $9.4 million benefit from change in fair value from our public equity investments and $4.9 million in costs related to the proposed acquisition by Siemens Healthineers. Additionally, it includes investments in cardiac radioablation. The Other segment is comprised of the Interventional Solutions business, including cryoablation, embolic microspheres, and microwave ablation. Other Segment Revenues for the Other segment were $9 million, down 54%. The company received one new system order in the quarter. Proton Solutions Segment Proton Solutions revenues totaled $26 million, down 7%. In Asia-Pacific, gross orders were down 12%. Gross orders in the Americas were down 4%, with flat growth in North America. Oncology Systems Segment Oncology Systems revenues totaled $744 million, down 5%. Net cash provided by operating activities was $141 million in the quarter. The company ended the quarter with $773 million in cash and cash equivalents and $210 million in debt. Reconciliation of GAAP and non-GAAP financial measures can be found at the end of the press release. Non-GAAP net earnings and non-GAAP net earnings per diluted share are defined as GAAP net earnings and GAAP net earnings per diluted share adjusted to exclude the amortization of intangible assets and amortization of inventory step-up, acquisition and integration-related expenses or benefits and in-process research and development, impairment charges, restructuring charges, significant litigation charges or benefits, legal costs, gains and losses on equity investments, and significant non-recurring tax expense or benefits. The transaction is expected to close in the first half of calendar year 2021, subject to regulatory approvals and other customary closing conditions. On October 15, 2020, Varian's stockholders voted in favor of the proposal to adopt the merger agreement with Siemens Healthineers. "Our long-term fundamentals remain strong and we are excited about the opportunity to shape the future of cancer care with the pending combination with Siemens Healthineers."Īs previously announced on August 2, 2020, Varian entered into a definitive agreement to combine with Siemens Healthineers AG (Frankfurt: SHL) in an all-cash transaction valued at $16.4 billion on a fully diluted basis. Our performance in the quarter reflects the unwavering focus of our employees to deliver critical cancer care solutions for our customers," said Dow Wilson, Chief Executive Officer of Varian. "I am pleased with our solid start to the fiscal year, especially given the current global landscape due to the pandemic. Varian (NYSE: VAR) today announced its first quarter fiscal year 2021 results.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |